Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced a significant milestone for its flagship Oncotype DX Breast Recurrence Score®test: ...
Comprehensive review confirms that the Oncotype DX Breast Recurrence Score ® test accurately predicts breast cancer outcomes and chemotherapy benefit for patients regardless of race or ethnicity ...
Researchers created a new blood test to identify cancers. The miONCO-Dx test utilizes blood samples and AI to detect signs of notable cancers like lung, prostate, ovarian, and breast cancers. This ...
Thermo Fisher Scientific TMO recently received approval from the Food and Drug Administration (“FDA”) for its Oncomine Dx Target Test as a companion diagnostic (CDx) to identify patients who may be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results